Acura Pharmaceuticals Secures Loan, Faces Bankruptcy Risk
Company Announcements

Acura Pharmaceuticals Secures Loan, Faces Bankruptcy Risk

Acura Pharmaceuticals (ACUR) has released an update.

Abuse Deterrent Pharma, LLC, controlled by Mr. Schutte, has provided a $250,000 loan to a company, increasing its total debt to $5,169,279, due by March 31, 2024, with a 5.25% interest rate, escalating to 7.5% upon default. The funds are earmarked for operational costs through mid-March, but the company warns of potential operational scale-back or bankruptcy if additional financing is not secured, posing a risk of complete shareholder value loss. AD Pharma currently owns around 65% of the company’s common stock, excluding warrants for an additional 10 million shares.

For further insights into ACUR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAcura Pharmaceuticals Announces Executive Leadership Transition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App